ATE550027T1 - Verwendung von pneumozyten des typs ii bei der behandlung von mit pulmonaler fibrose assoziierten lungenkrankheiten - Google Patents

Verwendung von pneumozyten des typs ii bei der behandlung von mit pulmonaler fibrose assoziierten lungenkrankheiten

Info

Publication number
ATE550027T1
ATE550027T1 AT06841789T AT06841789T ATE550027T1 AT E550027 T1 ATE550027 T1 AT E550027T1 AT 06841789 T AT06841789 T AT 06841789T AT 06841789 T AT06841789 T AT 06841789T AT E550027 T1 ATE550027 T1 AT E550027T1
Authority
AT
Austria
Prior art keywords
pneumocytes
treatment
type
diseases associated
pulmonary fibrosis
Prior art date
Application number
AT06841789T
Other languages
English (en)
Inventor
Mollar Ana Maria Serrano
Autet Daniel Closa
Moreu Jose Oriol Bulbena
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE550027T1 publication Critical patent/ATE550027T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42Respiratory system, e.g. lungs, bronchi or lung cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06841789T 2005-11-28 2006-11-27 Verwendung von pneumozyten des typs ii bei der behandlung von mit pulmonaler fibrose assoziierten lungenkrankheiten ATE550027T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200502939A ES2308877B1 (es) 2005-11-28 2005-11-28 Empleo de nuemocitos tipo ii en el tratamiento de enfermedades pulmonares que cursan con fibrosis pulmonar.
PCT/ES2006/070182 WO2007060278A1 (es) 2005-11-28 2006-11-27 Empleo de neumocitos tipo ii en el tratamiento de enfermedades pulmonares que cursan con fibrosis pulmonar

Publications (1)

Publication Number Publication Date
ATE550027T1 true ATE550027T1 (de) 2012-04-15

Family

ID=38066937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841789T ATE550027T1 (de) 2005-11-28 2006-11-27 Verwendung von pneumozyten des typs ii bei der behandlung von mit pulmonaler fibrose assoziierten lungenkrankheiten

Country Status (11)

Country Link
US (1) US9610305B2 (de)
EP (1) EP1961423B1 (de)
JP (1) JP5702521B2 (de)
AT (1) ATE550027T1 (de)
BR (1) BRPI0619353A2 (de)
CA (1) CA2631172C (de)
DK (1) DK1961423T3 (de)
ES (2) ES2308877B1 (de)
PL (1) PL1961423T3 (de)
PT (1) PT1961423E (de)
WO (1) WO2007060278A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3239292A4 (de) * 2014-12-24 2018-09-05 Ube Industries, Ltd. Zellkulturüberstandsflüssigkeit aus lungengewebe

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609412B2 (en) * 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
AU4520101A (en) 1999-12-07 2001-06-18 Childrens Hospital Los Angeles Research Institute Lung stem cells and lung regeneration
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
GB0218332D0 (en) * 2002-08-07 2002-09-18 Imp College Innovations Ltd Preparation of type pneumocytes
EP1654366A1 (de) * 2003-08-11 2006-05-10 University Of South Florida Stammzellen-beacon
WO2005040391A1 (en) * 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
EP1548100A1 (de) * 2003-11-11 2005-06-29 DeltaCell B.V. Inhibierung der differenzierung von stammzellen, förderung des wachstums und selektive induktion von apoptose durch wnt faktoren
ATE512212T1 (de) 2004-04-21 2011-06-15 Univ Minnesota Erzeugung von lungengewebe aus multipotenten adulten progenitorzellen (mapc)

Also Published As

Publication number Publication date
JP5702521B2 (ja) 2015-04-15
US20090220467A1 (en) 2009-09-03
ES2308877A1 (es) 2008-12-01
WO2007060278A1 (es) 2007-05-31
ES2308877B1 (es) 2009-10-26
US9610305B2 (en) 2017-04-04
PL1961423T3 (pl) 2012-09-28
ES2384564T3 (es) 2012-07-09
DK1961423T3 (da) 2012-06-25
JP2009517372A (ja) 2009-04-30
CA2631172C (en) 2014-08-05
EP1961423A1 (de) 2008-08-27
PT1961423E (pt) 2012-06-28
EP1961423B1 (de) 2012-03-21
BRPI0619353A2 (pt) 2011-09-27
CA2631172A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
NO20082096L (no) Azaindol-2-karboksamidderivativer
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
TNSN07272A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
MA32811B1 (fr) Nouveaux composés
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
ATE453642T1 (de) Substituierte phenylaminopyrimidine
EA201001639A1 (ru) Композиции и способы их получения и применения
UY31484A1 (es) Piperidinas heteroaril-sustituidas
BRPI0818581A2 (pt) Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
DK2215058T3 (da) Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
CY1112683T1 (el) Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους
MA32505B1 (fr) 5-alcynyl-pyrimidines
TW200700064A (en) Novel compounds
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate